|
|
|
Volumn 4, Issue 2, 2002, Pages 185-190
|
|
Technology evaluation: Adalimumab, Abbott laboratories
|
|
Author keywords
[No Author keywords available]
|
|
Indexed keywords
ADALIMUMAB;
D2E7;
ETANERCEPT;
GALACTOSAMINE;
HYBRID PROTEIN;
IMMUNOGLOBULIN G1;
INFLIXIMAB;
INTERLEUKIN 1BETA;
INTERLEUKIN 6;
INTERLEUKIN RECEPTOR;
INTERSTITIAL COLLAGENASE;
LIGAND;
METHOTREXATE;
PLACEBO;
PROTEIN P55;
PROTEIN P75;
STROMELYSIN;
TUMOR NECROSIS FACTOR ALPHA;
TUMOR NECROSIS FACTOR RECEPTOR 2;
UNCLASSIFIED DRUG;
MONOCLONAL ANTIBODY;
ANIMAL EXPERIMENT;
ANIMAL MODEL;
ANTIBODY SPECIFICITY;
ANTIGEN BINDING;
APLASTIC ANEMIA;
AREA UNDER THE CURVE;
ARTICLE;
AUTOIMMUNE DISEASE;
CLINICAL TRIAL;
CONTROLLED CLINICAL TRIAL;
CONTROLLED STUDY;
CROHN DISEASE;
DOSE RESPONSE;
DRUG APPROVAL;
DRUG BLOOD LEVEL;
DRUG HALF LIFE;
DRUG INDICATION;
DRUG MARKETING;
DRUG SYNTHESIS;
GENETIC ENGINEERING;
HUMAN;
INFLAMMATORY DISEASE;
ISCHEMIC HEART DISEASE;
MAJOR CLINICAL STUDY;
NEUROLOGIC DISEASE;
NEUTROPENIA;
NONHUMAN;
REINFECTION;
RHEUMATOID ARTHRITIS;
SKIN IRRITATION;
TOXICITY TESTING;
DRUG INDUSTRY;
EVALUATION;
PATENT;
STRUCTURE ACTIVITY RELATION;
ANTIBODIES, MONOCLONAL;
ARTHRITIS, RHEUMATOID;
DRUG INDUSTRY;
HUMAN;
PATENTS;
STRUCTURE-ACTIVITY RELATIONSHIP;
HUMANS;
ANIMALIA;
FELIS CATUS;
|
|
EID: 0035997965
PISSN: 14648431
EISSN: None
Source Type: Journal
DOI: None Document Type: Article |
|
Times cited : (28)
|
|
References (0)
|
